As per Global Insight services’ assessment, about 20+ prominent pharma and biotech giants are working on 20+ drugs in the Diabetic Gastroparesis – Drug Pipeline Landscape, 2023 globally. Diabetic Gastroparesis – Drug Pipeline Landscape, 2023 report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.
“Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key –https://www.globalinsightservices.com/request-sample/GIS31260
Diabetic Gastroparesis is a serious complication of diabetes resulting in delayed gastric emptying with associated upper gastrointestinal (GI) symptoms in the absence of any mechanical obstruction. Gastroparesis is a digestive disorder with a high incidence among people with long-standing diabetes.
Gastroparesis can cause due to the damage of vagus nerve. Certain medications, such as opioid pain relievers, some antidepressants, and high blood pressure and allergy medications, can lead to slow gastric emptying and cause similar symptoms.
Symptoms of diabetic gastroparesis includes nausea, vomiting and abdominal pain. It can also cause problems with blood sugar levels and nutrition, feeling of fullness after eating just a few bites, vomiting undigested food eaten a few hours earlier, acid reflux, changes in blood sugar levels, lack of appetite, weight loss and malnutrition.
Free customization available – https://www.globalinsightservices.com/request-customization/GIS31260
Doctors most often diagnose diabetic gastroparesis by using the tests such as scintigraphy, breath tests, upper gastrointestinal (GI) endoscopy, wireless motility capsule, barium X-ray, gastric manometry, radioisotope gastric-emptying scan.
The most common investigative treatments include metoclopramide (Reglan) and erythromycin. Surgery in some cases may improve outcomes. Symptoms can be eased through lifestyle changes and home remedies like eating smaller meals more frequently, avoid fibrous fruits and vegetables, drink about 34 to 51 ounces (1 to 1.5 liters) of water a day.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Diabetic Gastroparesis treatment such as CNSA-001, NG101, PCS12852. Key players involved in the development of therapies to treat diabetic gastroparesis are Neurograstx Inc, Processa Pharmaceuticals, PTC Therapeutics. Three drugs are under late-stage Phase II clinical trials stages of development.
In December 2022, Processa Pharmaceuticals announced that PCS12852 successfully improved the clinical symptoms associated with gastroparesis in phase 2A trial, further supporting to initiate Phase 2B trial in 2023
Buy your copy now: https://www.globalinsightservices.com/checkout/single_user/GIS31260
Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like
– Late-stage products (Phase III)
– Mid-stage products (Phase II)
– Early-stage product (Phase I)
– Pre-clinical and Discovery stage candidates
– Discontinued & Inactive candidates
About Global Insight Services:
Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.
Contact Us:
Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: i[email protected]
Phone: +1-833-761-1700
Website: https://www.globalinsightservices.com/